Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy

NCT00148772 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Erlotinib (Tarceva)

Sponsor

Endeavor Health

Collaborators

[object Object]
[object Object]